Paradigm Biopharmaceuticals (ASX:PAR) chief executive officer, Paul Rennie, joined Proactive's CEO Sessions in Melbourne on Tuesday 16th May and Sydney on Wednesday 17th May.
Paradigm has results from its Phase 2 hay fever trial pending in six weeks.